Each year, the FDA, World Health Organization, the Centers for Disease Control and Prevention and other public health experts collaborate on the review of influenza disease surveillance and laboratory data collected from around the world in an effort to identify strains that may cause the most illness in the upcoming season. Based on that information and on the recommendations of the FDAs Vaccines and Related Biological Products Advisory Committee, the FDA selects the different influenza strains each year that manufacturers should include in their vaccines for the U.S. population for the upcoming influenza season. The closer the match between the circulating strains causing disease and the strains in the vaccine, the better the protection against influenza.
Influenza Virus Vaccine Composition and Lot Release information from previous seasons is available in the FDA Archive. CBER will no longer post lot release information for seasonal influenza vaccines after June 2022.
Influenza Virus Vaccine Composition
- Influenza Vaccine for the 2023-2024 Season
- Influenza Vaccine for the 2022-2023 Season
- Influenza Vaccine for the 2021-2022 Season
- Influenza Vaccine for the 2020-2021 Season
- Influenza Virus Vaccine Safety & Availability
- Vaccines Licensed for Use in the United States
- Influenza A (H1N1) 2009 Monovalent Vaccines Composition and Lot Release
Resources For You
- Consumers (Biologics)
- Healthcare Providers (Biologics)
- Industry (Biologics)
- About the Center for Biologics Evaluation and Research (CBER)